Article

A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C

Division of International Health and Cross Cultural Medicine, University of California School of Medicine, 9500 Gilman Dr, Mailstop 0622, La Jolla, CA 92093, USA.
American Journal of Public Health (Impact Factor: 4.23). 06/2008; 98(5):853-61. DOI: 10.2105/AJPH.2007.113415
Source: PubMed

ABSTRACT We evaluated the efficacy of a peer-mentoring behavioral intervention designed to reduce risky distributive injection practices (e.g., syringe lending, unsafe drug preparation) among injection drug users with hepatitis C virus (HCV) infection.
A randomized trial with a time-equivalent attention-control group was conducted among 418 HCV-positive injection drug users aged 18 to 35 years in 3 US cities. Participants reported their injection-related behaviors at baseline and at 3- and 6-month follow-ups.
Compared with the control group, intervention-group participants were less likely to report distributive risk behaviors at 3 months (odds ratio [OR]=0.46; 95% confidence interval [CI]=0.27, 0.79) and 6 months (OR=0.51; 95% CI=0.31, 0.83), a 26% relative risk reduction, but were no more likely to cite their HCV-positive status as a reason for refraining from syringe lending. Effects were strongest among intervention-group participants who had known their HCV-positive status for at least 6 months. Peer mentoring and self-efficacy were significantly increased among intervention-group participants, and intervention effects were mediated through improved self-efficacy.
This behavioral intervention reduced unsafe injection practices that may propagate HCV among injection drug users.

Download full-text

Full-text

Available from: Richard S Garfein, Aug 17, 2015
2 Followers
 · 
117 Views
  • Source
    • "In lieu of SEPs, behavioral and clinical interventions may be applicable. Peer-driven and other behavioral interventions could also be considered as a way to reduce HCV risk behavior in this population [Garfein et al., 2007; Latka et al., 2008; Sacks-Davis et al., 2011]. Programs and funding to improve residents' access to health care and to drug treatment also could help to prevent and/or mitigate the long-term consequences of HCV infection. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Research has demonstrated that hepatitis C (HCV) genotype distribution varies geographically and demographically. This exploratory study examines HCV viremia, viral concentration, and genotype distribution among anti-HCV positive, rural Appalachian nonmedical prescription drug users. The study population was randomly selected from a pool of 200 anti-HCV positive participants in a longitudinal study. Those randomly chosen were representative of the overall pool in terms of demographics, drug use, and other risk behaviors. Participants were tested serologically for HCV RNA, viral concentration, and genotype, and interview-administered questionnaires examined behavioral and demographic characteristics. Of the 81 participants, 69% tested RNA positive, 59% of which had viral loads exceeding 800,000 IU/ml. Approximately 66% of the RNA positive sample had genotype 1a; types 2b (16%) and 3a (13%) were less common. RNA positive participants were not significantly different than RNA negative participants demographically or behaviorally. Likewise, with the exception of education, genotype 1 participants were not significantly different than those with genotype 2 or 3. The prevalence of active HCV infection highlights a need for prevention and treatment in this population. However, the predominance of genotype 1 may present challenges due to its association with decreased responsiveness to drug treatment, although the novel class of direct-acting antivirals such as telaprevir and boceprevir offer new hope in this regard. The prevalence of genotype 1 may also foreshadow heightened burden of hepatocellular carcinoma and elevated healthcare expenditures. More research is needed to characterize HCV infection and genotype in this population.
    Journal of Medical Virology 09/2012; 84(9):1376-87. DOI:10.1002/jmv.23252 · 2.22 Impact Factor
  • Source
    • "Gaining HCV vaccine trial and prevention knowledge may generate benefits that are twofold; it may serve to directly increase individual knowledge as well as providing an opportunity for PWID to accomplish altruistic goals of communicating knowledge within their social networks, which, in turn, may increase the value of trial participation for individual PWID. Peer-driven interventions are increasingly important and have been shown to be effective in reducing injection risk behaviours among HCV negative (Garfein et al., 2007; Mackesy-Amiti et al., 2011), HCV positive (Latka et al., 2008) and mixed (Tobin et al., 2011) populations of PWID, and may optimise prevention efforts in future vaccine trials. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A safe and efficacious vaccine may be the most efficient and cost-effective strategy for controlling the hepatitis C virus (HCV) epidemic among people who inject drugs (PWID) and several candidates are in development. However, little is known about the factors that influence willingness to participate (WTP) in candidate HCV vaccine trials among this group. HCV seronegative PWID recruited between 2008 and 2010 as part of a prospective observational cohort study in Sydney, Australia were asked whether they would be willing to participate in a future candidate hepatitis C vaccine trial and to provide reasons to explain their decision. Of 113 participants, 74% indicated WTP, 15% were unwilling to participate and 11% reported WTP that was contingent on vaccine characteristics and trial design issues. The most commonly reported motivator for hypothetical trial participation was altruism, followed by potential health benefits, financial remuneration, and knowledge gain. Barriers to hypothetical participation included fears about possible harms to health, such as concerns about vaccine safety, side effects, and acquiring HCV from the vaccine; other barriers included mistrust of biomedical research and time constraints. These results may be useful in designing strategies to enhance HCV vaccine trial recruitment and retention and have ethical implications for developing informed consent processes and standards of care.
    Drug and alcohol dependence 11/2011; 123(1-3):35-40. DOI:10.1016/j.drugalcdep.2011.10.009 · 3.28 Impact Factor
  • Source
    • "By chance, participants randomized to the intervention group reported less alcohol use at baseline than did those in the control arm. This lack of balance in randomization was also noted when examining efficacy of this intervention in reducing distributive needle sharing [17]. However , this was unlikely to affect our analyses as there were no observed effects of the intervention on reported alcohol use, self-reported alcohol use was adjusted for in models examining the effect of the intervention on ALT and AST, and other measures of alcohol use examined changes in behavior, which would have been detected regardless of baseline use. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) screening can provide opportunities to reduce disease progression through counseling against alcohol use, but empirical data on this issue are sparse. We determined the efficacy of a behavioral intervention in reducing alcohol use among young, HCV-infected injection drug users (IDUs) (n=355) and assessed whether changes in liver enzymes were associated with changes in alcohol consumption. Both the intervention and attention-control groups were counseled to avoid alcohol use, but the intervention group received enhanced counseling. Logistic regression, ANOVA, and continuous time Markov models were used to identify factors associated with alcohol use, changes in mean ALT and AST levels, and change in alcohol use post-intervention. Six months post-intervention, alcohol abstinence increased 22.7% in both groups, with no difference by intervention arm. Transition from alcohol use to abstinence was associated with a decrease in liver enzymes, with a marginally greater decrease in the intervention group (p=0.05 for ALT; p=0.06 for AST). In multivariate Markov models, those who used marijuana transitioned from alcohol abstinence to consumption more rapidly than non-users (RR=3.11); those who were homeless transitioned more slowly to alcohol abstinence (RR=0.47); and those who had ever received a clinical diagnosis of liver disease transitioned more rapidly to abstinence (RR=1.88). Although, behavioral counseling to reduce alcohol consumption among HCV-infected IDUs had a modest effect, reductions in alcohol consumption were associated with marked improvements in liver function. Interventions to reduce alcohol use among HCV-infected IDUs may benefit from being integrated into clinical care and monitoring of HCV infection.
    Journal of Hepatology 11/2010; 55(1):45-52. DOI:10.1016/j.jhep.2010.10.028 · 10.40 Impact Factor
Show more